Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents

October 1, 2018

A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.

Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says

All Content © 2018, Portfolio Media, Inc.

Related Publications

June 2020
Trade Secrets: Safe as Houses
Christopher Larus, David Prange, Alyssa Bixby-Lawson - Intellectual Property Magazine
June 4, 2020
May 6, 2020
Hatch-Waxman Litigation Venue Update Post-Google
Kelsey McElveen, Ellen Levish - Bloomberg Law
May 4, 2020
Explaining The Almost Unexplainable: Source Code Evidence At Trial
David Prange, Benjamen Linden - LegalTech News
April 7, 2020
Protecting Confidential Information When Sheltering in Place
David Prange, Chris Larus - Corporate Counsel
Back to Top